Key Financial Data Of Group

SAPPORO CLINICAL LABORATORY INC. - Filing #7325055

Concept As at
2024-03-31
As at
2024-03-31
As at
2024-03-31
As at
2024-03-31
As at
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2024-03-31
As at
2024-03-31
2022-04-01 to
2023-03-31
As at
2023-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
As at
2022-03-31
As at
2022-03-31
As at
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
As at
2021-03-31
2019-04-01 to
2020-03-31
As at
2020-03-31
2019-04-01 to
2020-03-31
As at
2020-03-31
Key financial data of group
Business results of group
Net sales
17,333,697,000 JPY
19,682,319,000 JPY
17,613,669,000 JPY
20,127,692,000 JPY
17,737,144,000 JPY
19,109,595,000 JPY
16,372,822,000 JPY
17,502,544,000 JPY
16,507,881,000 JPY
17,659,084,000 JPY
Ordinary profit (loss)
598,333,000 JPY
514,777,000 JPY
895,308,000 JPY
1,159,449,000 JPY
1,567,931,000 JPY
1,605,618,000 JPY
1,170,964,000 JPY
1,188,144,000 JPY
944,056,000 JPY
982,982,000 JPY
Profit (loss) attributable to owners of parent
380,156,000 JPY
568,619,000 JPY
1,042,882,000 JPY
793,688,000 JPY
528,204,000 JPY
Comprehensive income
410,656,000 JPY
649,366,000 JPY
1,019,339,000 JPY
843,471,000 JPY
516,047,000 JPY
Net assets
11,183,039,000 JPY
10,640,704,000 JPY
10,212,467,000 JPY
10,880,986,000 JPY
10,337,959,000 JPY
9,839,022,000 JPY
9,272,384,000 JPY
9,014,231,000 JPY
8,463,145,000 JPY
8,209,868,000 JPY
Total assets
16,680,947,000 JPY
15,057,391,000 JPY
14,487,068,000 JPY
16,521,281,000 JPY
16,149,449,000 JPY
14,440,322,000 JPY
14,511,471,000 JPY
13,662,749,000 JPY
11,553,144,000 JPY
10,708,787,000 JPY
Net assets per share
3,283.71
3,194.85
3,066.27
3,178.25
3,016.24
2,934.15
2,708.63
2,633.22
2,472.23
2,398.25
Basic earnings (loss) per share
138.25
114.14
141.47
170.53
300.67
306.16
231.10
231.85
147.04
154.30
Diluted earnings per share
Equity-to-asset ratio
0.656 xbrli:pure
0.707 xbrli:pure
0.705 xbrli:pure
0.641 xbrli:pure
0.626 xbrli:pure
0.681 xbrli:pure
0.639 xbrli:pure
0.660 xbrli:pure
0.733 xbrli:pure
0.767 xbrli:pure
Rate of return on equity
0.044 xbrli:pure
0.035 xbrli:pure
0.047 xbrli:pure
0.055 xbrli:pure
0.109 xbrli:pure
0.108 xbrli:pure
0.092 xbrli:pure
0.090 xbrli:pure
0.063 xbrli:pure
0.064 xbrli:pure
Price-earnings ratio
7.86 xbrli:pure
9.51 xbrli:pure
8.96 xbrli:pure
7.43 xbrli:pure
4.31 xbrli:pure
4.23 xbrli:pure
6.63 xbrli:pure
6.61 xbrli:pure
10.87 xbrli:pure
10.36 xbrli:pure
Net cash provided by (used in) operating activities
1,077,593,000 JPY
1,430,350,000 JPY
1,573,628,000 JPY
837,590,000 JPY
1,255,547,000 JPY
Net cash provided by (used in) investing activities
-395,474,000 JPY
-409,028,000 JPY
-830,960,000 JPY
-3,148,264,000 JPY
-2,913,165,000 JPY
Net cash provided by (used in) financing activities
-369,961,000 JPY
-347,894,000 JPY
-112,738,000 JPY
1,943,634,000 JPY
-51,630,000 JPY
Cash and cash equivalents
3,966,205,000 JPY
3,654,048,000 JPY
2,980,620,000 JPY
2,350,691,000 JPY
2,717,730,000 JPY
Number of employees
324 xbrli:pure
287 xbrli:pure
21 xbrli:pure
287 xbrli:pure
539 xbrli:pure
21 xbrli:pure
3 xbrli:pure
21 xbrli:pure
871 xbrli:pure
3 xbrli:pure
635 xbrli:pure
627 xbrli:pure
938 xbrli:pure
871 xbrli:pure
622 xbrli:pure
819 xbrli:pure
775 xbrli:pure
820 xbrli:pure
779 xbrli:pure

Talk to a Data Expert

Have a question? We'll get back to you promptly.